Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Tanzeum Launch Marks The Big Pharma’s Return To Diabetes

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK expects Tanzeum will be one of its “core big six” drugs despite the fact that it is the fourth GLP-1 to market. VP-General Medicines Cheryl MacDiarmid discussed GSK’s return to diabetes in an interview.

Advertisement

Related Content

J&J Prepares For US Sirukumab Launch After Regaining Rights From GSK
Changing Face Of ‘Me Too’ Drugs On Display In 2014 NME Approvals
Changing Face Of ‘Me Too’ Drugs On Display In 2014 NME Approvals
FDA Replaces Avandia REMS Distribution Restrictions With Prescriber Training
FDA Keeps Avandia On The Market But Looks To RECORD For More Clarity On CV Risk
GSK Will End Avandia Promotion Worldwide
Avandia Safety Under The Microscope

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077494

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel